Many past trials have shown the safety of Brilacidin at the trial dosage level, and higher, so one would not expect to be having safety issues in this trial.

That leaves only efficacy, and with a selectivity index (SI) of 426, if Brilacidin is not effective why even bother with an SI as it obviously isn't worth squat? And we are all expecting extremely high efficacy, when in reality the bar we have to beat is exceedingly low so there shouldn't be any worry about doing that. But in reality, anything less than spectacular will be a disappointment to many strong longs.

I will beyond shocked if trial doesn't turn out exceedingly well for Brilacidin.